Jordan Registration Review Timelines: Official Limits and Practical Reality

1. Key takeaways

The JFDA dossier processing time limit published on the Jordan Trade Portal is a maximum of 60 working days from the date of submission of a complete dossier. The point GRZAN wishes to flag is this: that figure is the officially published processing time limit, whereas the actual cycle in industry practice usually falls in the 4 to 8 month range (practical estimate). The gap between the two is not a matter of poor execution, but a difference in the counting start point and in the process variables. Companies that understand which variables move the cycle can manage it; companies that only track the official figure will keep missing their launch windows.

• The second conclusion: the practical cycle tiers by risk class — Class I approximately 4 months, Class IIa approximately 4 months, Class IIb approximately 4 to 8 months, Class III approximately 8 months; if local sample testing is triggered, the cycle extends further (practical estimate).
• The third conclusion: the gap comes mainly from three structural variables — the point at which the dossier is deemed “complete”, the number of deficiency response rounds, and the insertion of local testing. Companies should plan their schedules on practical estimates and use the official time limit as the communication baseline.

2. Legal basis

Time limits follow the official publication on the Jordan Trade Portal; the practical cycles are industry experience estimates, not officially published values.

3. Expert insights

Insight 1: a “complete dossier” is the precondition for the time limit to start running. The official limit runs from “the date of submission of a complete dossier”, and the determination of whether the dossier is complete rests with JFDA. If the first submission is judged incomplete, the time limit has not yet started while the project has already consumed several weeks. GRZAN treats the quality of the first submission as the first lever of cycle management. Every week saved by not having to be re-judged as incomplete is a week gained at the front of the project, where it is worth most.

Insight 2: two figures circulate for the deficiency response period. Industry materials contain both a 30 day and a 60 day formulation of the deficiency response period. GRZAN’s handling principle is that the period stated in JFDA’s specific deficiency notice prevails, and GRZAN recommends starting the response immediately upon receiving the notice rather than using up the full period (practical estimate). Responding early also shortens the perceived round-trip: a complete, prompt answer removes the need for a follow-up clarification and keeps the file moving.

Insight 3: local testing is the largest cycle variable. Class IIb and Class III devices may be required to send samples to the Royal Scientific Society (RSS) of Jordan or to the JFDA central laboratory for local testing, a step that stretches the overall cycle by a further several weeks to several months (practical estimate). Whether it is triggered depends on the product risk and the sufficiency of the existing test reports; not all products trigger it. The uncertainty, however, applies to the whole class: until the review confirms the testing arrangement, the local testing option has to be carried in the plan as a live possibility.

Insight 4: the 2025 circular converts cycle risk into customs clearance risk. After Circular No. 54863/1/5 (9 October 2025) took effect, Class IIb devices cannot be imported without completed registration. Timeline uncertainty is therefore no longer merely a matter of “late market entry”, but one of “goods arriving at port without clearance”. This conversion changes the amount of cycle buffer a company needs. A schedule risk that used to cost market timing now costs storage, demurrage and re-booking of shipments, so the buffer must be sized in money as well as in weeks.

Insight 5: consular legalisation and document preparation are independent variables outside the cycle. The notarisation and consular legalisation of the FSC and the letter of authorisation usually take 4 to 6 weeks (practical estimate); this time does not count within the JFDA review cycle, yet it determines whether the project can start. A project that treats the legalisation chain as an afterthought will find its review clock frozen at zero while the paperwork is still in transit.

4. Practical recommendations

• Schedule on practical estimates; speak to clients on the official basis. When committing delivery dates externally, use 4 to 8 months as the baseline; when communicating with JFDA, use the 60 working days as the dialogue baseline. Keeping the two baselines visibly separate prevents commitments made to customers from being silently inherited by the regulatory team.
• Treat the quality of the first submission as the top priority of cycle management. GRZAN recommends completing one internal compliance review before submission, checking the items against the document list one by one.
• Reserve a buffer for local testing. Class IIb and Class III products should carry additional testing time in the plan (practical estimate).
• For Class IIb products, place the registration completion point ahead of the shipping plan. Goods arriving at port without a registration certificate will incur port demurrage costs.

5. Verification checklist

• □ Build the project plan on a 4 to 8 month practical cycle (practical estimate)
• □ Confirm the completeness of the first-submission documents, to avoid a delayed “complete dossier” determination
• □ Start the response immediately upon receiving a deficiency notice; the period stated in the notice prevails
• □ Reserve local testing time for Class IIb and Class III products (practical estimate)
• □ Reserve 4 to 6 weeks for the consular legalisation of the FSC and the letter of authorisation (practical estimate)
• □ Check whether the registration completion milestone for Class IIb products precedes the shipping milestone
• □ Recheck the time limit formulations against the Jordan Trade Portal and official JFDA announcements
• □ Regulatory information verified as of 29 October 2026

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Jordanian market. Our team manages JFDA registration applications, prepares reference-approval dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzan.com